Hey buddy I'm here, patiently waiting in the wings. I liked the presentation as well. A little dry and clearly more scientific based than what most Wall st types want to hear, but the science seemed solid, they are really looking to hit a home run here, the level of microbiology and bone resorption analysis they have been willing to address, acknowledge, and pursue is unheard of. Feel they did well to avoid it being a purely PR/hype based conference. Those guys on the panel were legit, as boring as any I've ever listened to at high level conferences lol.
I think it would've been a large error to pay for the conference/PR without having prelim data analyses at least (which is fairly typical to have), I don't find it reasonable or believable to believe that mgmt has no concept of data, given the overall picture and timeline, and companies will usually acknowledge freely that their field researchers don't have data, as a component of running double blind, which is usually all they are required or willing to say. I also found it funny that they made no generalizations or vague links to pending data, ominously absent, and thankfully offered no hints about future directions or problem spots in the science, which seems very relevant on the brink of news. So I sit and wait lol. Hearing the sheer volume of studies and research they have accumulated in this field was eye opening. I was thoroughly impressed to see the level of knowledge they have in this area, and the working knowledge they have of FDA tracks and approvals avenues- a piece that is classically missing from discussions led by new companies... so it was surprising to see the level of thought they are using to approach. So I was a bit surprised and enthusiastic to hear their thoughts on potentials for our compound to (potentially) favorably impact bone remodeling and fracture healing, independent of the muscle growth. As an analogy, Instead of just throwing gasoline into an engine and boosting mood and offering short term gains that fade, they hint at the potential for our compound to change the mechanics of the car, to modify the rubber on the torn tires... this is a huge angle they are looking at as proof of concept... truly cannot be understated. If they are able to link the data and get in depth analyses of the long term bone effects, our drug could then be used off label in a number of pathological fracture scenarios with other fracture sites... making it an unlimited market. I still find it a stretch, and more of a dream, at this stage. That being said, if they can create a scenario where our drug shows independently favorable bone health and repair benefits, this has the potential to be a panacea for fracture care in elderly populations. Using it on people with less to lose (end of life, high mortality fractures) is a great place to get the data they would need, that would open this up to less terminal participants. It also makes their bone/muscle more generalized approach seemingly much better thought out than the niche indication that GTXI is exploring, that will likely restrict GTXI from entering our areas as competition, without a lot of additional trials on their end.
I have finalized my position for trial results, and hold about 3/4 of my original warrant position, along with about 1/4 of my common position. Very excited for the weeks ahead. If data looks good, I will probably abandon another 25% of my warrants, and close my common position. Wish I had the patience to hold it all through both trials, but for whatever reason my sleep is less restful with unspeakable sums of money tied into one stock ;)
Hope you're enjoying the ride buddy, the waiting game continues, take care
